Home Compare AU vs ZEAL.CO
Stock Comparison · Single-driver result

AngloGold Ashanti vs Zealand Pharma A/S: Which Stock Looks Stronger in 2026?

The structural profiles are close, with AngloGold Ashanti carrying a narrow edge on stability. The remaining gap is narrow enough that the comparison remains open to different readings. On the market side, AngloGold Ashanti is in better shape — its trend is intact while Zealand Pharma A/S's trend has broken down. That puts structure and market broadly in agreement — AngloGold Ashanti's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Most of the separation is still concentrated in stability.

Trajectory Similarity
0.63
Moderately similar
Peer-set rank: #5
within AngloGold Ashanti plc's functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

The pair shares a valid long-term profile match, but the trajectories are not especially close.

The match is driven mainly by investment intensity and operating margin level.

Similarity drivers
investment intensityoperating margin level
What reduces the match
recent revenue growth
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
AU
AngloGold Ashanti plc
86
Peer-Score
Signal qualityMedium
vs
ZEAL.CO
Zealand Pharma A/S
84
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in stability.

Dimension spread: AU vs ZEAL.CO Profitability 96 100 Stability 61 36 Valuation 84 88 Growth 100 100 AU ZEAL.CO
Gap Ranking
#1 Stability +25
#2 Profitability +4
#3 Valuation +4
#4 Growth
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AU and ZEAL.CO Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AUZEAL.CO Relative valuation Structural strength

Zealand Pharma A/S and AngloGold Ashanti plc look relatively close on structure, but the price setup still leans toward Zealand Pharma A/S.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Stability
On stability, AngloGold Ashanti plc is positioned higher in the group, while Zealand Pharma A/S is closer to the middle.
Stability — Dominant Gap
AU
61
ZEAL.CO
36
Gap+25in favour of AU

The stability gap is wide, with the stronger side looking materially steadier through time.

What else supports the lead

Market confirmation also leans toward AngloGold Ashanti plc, which makes the lead look better backed by actual market behaviour.

What this means for the comparison

The main read on stability is clearer than the broader score gap.

Explore full peer positioning in AssetNext

Break down the AU vs ZEAL.CO comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar stability-driven comparisons

Explore how AU and ZEAL.CO each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.